| Literature DB >> 29449829 |
Mansour Amraei1,2, Safoura Mohamadpour3, Kourosh Sayehmiri3, Seyedeh Fatemeh Mousavi3, Ehsan Shirzadpour1, Ardeshir Moayeri4.
Abstract
INTRODUCTION: Proper nutrition is important for overall health, and it reduces healthcare costs associated with malnutrition. Many studies have investigated vitamin D deficiency and its role in gestational diabetes and controversial data have reported. A comprehensive consideration of articles in this field provides the possibility of a general study of this relationship. This meta-analysis is an evaluation of the relationship between vitamin D deficiency and gestational diabetes.Entities:
Keywords: gestational diabetes mellitus; meta-analysis; pregnancy; systematic review; vitamin D deficiency
Year: 2018 PMID: 29449829 PMCID: PMC5800395 DOI: 10.3389/fendo.2018.00007
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Flowchart of the literature search.
Characteristics and information of studies evaluated in this meta-analysis.
| Reference | Country | Study design | Sample size ( | Age at baseline (year) | Current status | Assay method for vitamin D | Mean 25(OH)D nmol/L (SD) | Significant | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GDM | NGT | GDM | NGT | |||||||
| ( | Australia | Cross-sectional | 81 | 226 | 32.6 | Second or Third trimester | LC–MS | 48.6 (24.9) | 55.3 (23.3) | No |
| ( | US | Nested Case–control | 57 | 114 | 33.5 | 24–28 weeks | ELISA | 60.4 (21.22) | 75.13 (24.21) | Yes |
| ( | Iran | Cross-sectional | 52 | 579 | 25.6 | 24–28 weeks | RIA | 16.49 (10.44) | 22.97 (18.25) | No |
| ( | India | Cross-sectional | 39 | 520 | 23.7 | <32 weeks | RIA | 49.3 (31.2) | 46.4 (30.9) | No |
| ( | Iran | Case–control | 54 | 111 | 27.4 | 24–28 weeks | ELISA | 24.01 (20.62) | 32.2 (35.74) | No |
| ( | UK | Case–control | 90 | 158 | 33.5 | First trimester | LC–MS | 47.2 (26.7) | 47.6 (26.7) | No |
| ( | UK | Case–control | 100 | 1,000 | 31.7 | 11–19 weeks | LC–MS | NR | NR | No |
| ( | US | Nested-case–control | 60 | 120 | 33.7 | 24–28 weeks | LC–MS | 97.0 (29.0) | 86.0 (22.0) | No |
| ( | Canada | Nested-case–control | 116 | 218 | 34.3 | 15–18 weeks | CLIA | 56.3 (19.4) | 62 (21.6) | No |
| ( | China | Nested-case–control | 200 | 200 | 32 | 26–28 weeks | ELISA | 22.4 (10.7) | 25.9 (12.3) | Yes |
| ( | Spain | Cross-sectional | 36 | 466 | NR | 11–14 weeks | ECLIA | NR | NR | NR |
| ( | Spain | Cross-sectional | 49 | 266 | NR | 24–28 weeks | CLIA | NR | NR | No |
| ( | US | Cross-sectional | 68 | 1,264 | 32 | 26–28 weeks | CLIA | NR | NR | No |
| ( | Turkey | Cross-sectional | 234 | 168 | 30.8 | 24–28 weeks | ECLIA | 30.8 (16.3) | 36.0 (16.2) | Yes |
| ( | Qatari | Cohort | 260 | 1,613 | >24 weeks | RIA | 44.19 (20.01) | NR | Yes | |
| ( | Turkey | Case-control | 44 | 78 | 26.4 | 24–32 weeks | CLIA | 48.67 (23.21) | 57.16 (24.96) | Yes |
| ( | Australia | Nested case–control | 376 | 3,714 | 33.2 | First trimester | AIAS | 56.9 (26.9) | 52.1 (22.1) | No |
| ( | Canada | Cross-sectional | 54 | 601 | 28.4 | 6–13 weeks | LC–MS | 57.5 (17.2) | 63.5 (18.9) | No |
| ( | Korea | Cohort | 23 | 500 | 33.7 | 24–28 weeks | ECLIA | 49.4 (19.4) | 48 (24.8) | No |
| ( | China | Cohort | 2,960 | 100 | 29.7 | 16–20 weeks | ECLIA | NR | NR | No |
| ( | Spain | Cohort | 93 | 2,289 | 32 | 13.5 weeks | HPLC | 28.42 (4.39) | 28.41 (0.96) | No |
| ( | Canada | Cohort | 142 | 125 | 34.4 | NR | ECLIA | NR | NR | No |
| ( | US | Nested-case–control | 135 | 517 | 33.5 | 18–22 weeks | LC–MS | 59.7 (23.5) | 66.6 (22) | No |
| ( | Czech | Case–control | 47 | 29 | 33 | 24–30 weeks | EIASA | 28.5 (13) | 31.7 (16) | No |
| ( | Iran | Case–control | 43 | 44 | 31.28 | First trimester | Liebermann–Burchard method | 33.54 (18.88) | 43.23 (37.02) | Yes |
| ( | India | Case–control | 51 | 19 | 26.5 | <28 weeks | RIA | 24.7 (17.6) | 45.8 (28) | Yes |
Significant: significant difference in serum 25(OH)D between NGT and GDM.
.
NR, not reported; LC–MS, liquid chromatography-tandem mass spectrometry; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; CLIA, chemiluminescence immunoassay; ECLIA, ElectroChemiLuminescence immunoassay; AIAS, automated immunoassay system; HPLC, high-performance liquid chromatography.
Figure 2Relationship between insufficient vitamin D and risk of GDM.
Figure 3Relationship between serum 25(OH)D level and GDM.
Figure 4Relationship between serum 25(OH)D level and GDM based on study design.
Figure 5Relationship between serum 25(OH)D level and GDM based on region.
Figure 6Funnel plot (from Begg–Mazumdar test) for publication bias.
Figure 7Begg–Mazumdar rank correlation and Egger regression tests for publication bias. OR, odds ratio.